IMRN vs KZIA
Immuron Ltd. and Kazia Therapeutics Ltd., side by side — 8 fiscal years reported in AUD, drawn from SEC filings.
Most recent reported year
| Metric | IMRN | KZIA |
|---|---|---|
| Revenue | AUD 7.3M | AUD 42,000 |
| Net income | AUD -5.2M | AUD -20.7M |
| Gross margin | 65.4% | · |
| Net margin | −71.6% | · |
| Return on equity | −50.2% | · |
| Diluted EPS | −AUD 2.26 | −AUD 0.04 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | · | · |
| Equity | · | AUD -8.3M |
| Net debt / equity | · | · |
| Current ratio | 5.09× | 0.35× |
| Revenue CAGR 5y | 23.7% | · |
| Profit CAGR 5y | · | · |
IMRN bills 173.5× the revenue of KZIA, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
8 years side by side
| Fiscal year | IMRN | KZIA |
|---|---|---|
| FY2024 | AUD 7.3M | AUD 42,000 |
| FY2023 | AUD 4.9M | AUD 2.3M |
| FY2022 | AUD 1.8M | AUD 0 |
| FY2021 | AUD 765,193 | AUD 0 |
| FY2020 | AUD 145,776 | AUD 15.2M |
| FY2017 | AUD 1.8M | AUD 119,000 |
| FY2016 | AUD 1.4M | AUD 249,000 |
| FY2015 | AUD 1.0M | AUD 406,000 |
Bottom line
| Fiscal year | IMRN | KZIA |
|---|---|---|
| FY2024 | AUD -5.2M | AUD -20.7M |
| FY2023 | AUD -6.9M | AUD -26.8M |
| FY2022 | AUD -3.8M | AUD -20.5M |
| FY2021 | AUD -2.9M | AUD -25.0M |
| FY2020 | AUD -8.4M | AUD -8.4M |
| FY2017 | AUD -3.1M | AUD -6.0M |
| FY2016 | AUD -6.8M | AUD -10.7M |
| FY2015 | AUD -7.1M | AUD -12.1M |
8 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2024 | +AUD 7,245,002 | IMRN |
| FY2023 | +AUD 2,594,865 | IMRN |
| FY2022 | +AUD 1,804,705 | IMRN |
| FY2021 | +AUD 765,193 | IMRN |
| FY2020 | −AUD 15,037,224 | KZIA |
| FY2017 | +AUD 1,723,909 | IMRN |
| FY2016 | +AUD 1,147,197 | IMRN |
| FY2015 | +AUD 595,077 | IMRN |
The higher-revenue side has changed between IMRN and KZIA over this period. The gap has widened since the earliest year compared.
8 of 10 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
KZIA's return on equity has been more volatile than IMRN's over the 7 comparable fiscal years — 36.5 percentage points of standard deviation against 28.1.
7 of 10 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between IMRN and KZIA over these 7 fiscal years — IMRN led in 4 and KZIA in 3.
7 of 10 comparable fiscal years — a year missing data on either side is not counted.